ClinicalTrials.govpublic full text
A Phase 1, Randomized, Blinded, Dose-escalation Study of rAAV1-PG9DP Recombinant AAV Vector Coding for PG9 Antibody in Healthy Male Adults.
hiv infections, hiv, aids, hiv vaccine, hiv prevention, aav, pg9, interventional, phase1
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗
Related documents
Record · ID 878809
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.